Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...